- Home
- ALLO vs ALT Comparison
ALLO vs ALT Comparison
Compare ALLO & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLO
- ALT
- Stock Information
- Founded
- ALLO 2017
- ALT 1997
- Country
- ALLO United States
- ALT United States
- Employees
- ALLO N/A
- ALT N/A
- Industry
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- ALT Biotechnology: Pharmaceutical Preparations
- Sector
- ALLO Health Care
- ALT Health Care
- Exchange
- ALLO Nasdaq
- ALT Nasdaq
- Market Cap
- ALLO 438.2M
- ALT 529.9M
- IPO Year
- ALLO 2018
- ALT N/A
- Fundamental
- Price
- ALLO $1.92
- ALT $6.23
- Analyst Decision
- ALLO Strong Buy
- ALT Strong Buy
- Analyst Count
- ALLO 10
- ALT 8
- Target Price
- ALLO $10.06
- ALT $19.71
- AVG Volume (30 Days)
- ALLO 3.0M
- ALT 2.7M
- Earning Date
- ALLO 11-07-2024
- ALT 11-12-2024
- Dividend Yield
- ALLO N/A
- ALT N/A
- EPS Growth
- ALLO N/A
- ALT N/A
- EPS
- ALLO N/A
- ALT N/A
- Revenue
- ALLO $43,000.00
- ALT $52,000.00
- Revenue This Year
- ALLO N/A
- ALT N/A
- Revenue Next Year
- ALLO N/A
- ALT N/A
- P/E Ratio
- ALLO N/A
- ALT N/A
- Revenue Growth
- ALLO 26.47
- ALT N/A
- 52 Week Low
- ALLO $1.78
- ALT $5.28
- 52 Week High
- ALLO $5.78
- ALT $14.84
- Technical
- Relative Strength Index (RSI)
- ALLO 39.98
- ALT 31.70
- Support Level
- ALLO $2.11
- ALT $7.13
- Resistance Level
- ALLO $2.40
- ALT $7.83
- Average True Range (ATR)
- ALLO 0.17
- ALT 0.46
- MACD
- ALLO 0.00
- ALT -0.13
- Stochastic Oscillator
- ALLO 15.79
- ALT 1.94
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.
About ALT Altimmune Inc.
Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.